ATXI (Avenue Therapeutics) E10: $-970.42 (As of Mar. 2026)


ATXI Avenue Therapeutics Inc ATXI
31 GF Score
Price $0.32
! 1 Warning Sign
View Full Analysis

What is Avenue Therapeutics E10?

Avenue Therapeutics ATXI +3.11% 31 E10 is $-970.42 as of Mar. 2026. GuruFocus rates ATXI with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Avenue Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.210. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-970.42 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-26), Avenue Therapeutics's current stock price is $0.315. Avenue Therapeutics's E10 for the quarter that ended in Mar. 2026 was $-970.42. Avenue Therapeutics's Shiller PE Ratio of today is .


Avenue Therapeutics  (OTCPK:ATXI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Avenue Therapeutics E10 Related Terms


Avenue Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Avenue Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avenue Therapeutics E10 Chart

Avenue Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -970.43

Avenue Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -997.58 -970.43 -970.42

ATXI vs PTIX, EVFM, AGTX: E10 Comparison

For the Biotechnology subindustry, Avenue Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avenue Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's Shiller PE Ratio falls into.


ATXI
31GF Score
Avenue Therapeutics Inc ATXI
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avenue Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Avenue Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.21/330.2130*330.2130
=-0.210

Current CPI (Mar. 2026) = 330.2130.

Avenue Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -98.104 241.018 -134.410
201609 -69.220 241.428 -94.676
201612 -103.703 241.432 -141.837
201703 -74.278 243.801 -100.605
201706 -787.500 244.955 -1,061.594
201709 -337.500 246.819 -451.533
201712 -708.750 246.524 -949.354
201803 -1,158.750 249.554 -1,533.273
201806 -506.250 251.989 -663.403
201809 -281.250 252.439 -367.900
201812 -416.250 251.233 -547.106
201903 -922.500 254.202 -1,198.344
201906 -483.750 256.143 -623.638
201909 -157.500 256.759 -202.558
201912 -371.250 256.974 -477.058
202003 -90.000 258.115 -115.139
202006 -123.750 257.797 -158.512
202009 -67.500 260.280 -85.636
202012 -67.500 260.474 -85.572
202103 -67.500 264.877 -84.150
202106 -67.500 271.696 -82.038
202109 -59.250 274.310 -71.325
202112 -55.500 278.802 -65.734
202203 -153.750 287.504 -176.590
202206 -30.750 296.311 -34.268
202209 -33.750 296.808 -37.548
202212 9.034 296.797 10.051
202303 -101.570 301.836 -111.119
202306 -38.740 305.109 -41.927
202309 4.860 307.789 5.214
202312 1.875 306.746 2.018
202403 -15.400 312.332 -16.282
202406 -6.430 314.175 -6.758
202409 -1.920 315.301 -2.011
202412 1.480 315.605 1.549
202503 -0.620 319.799 -0.640
202506 0.110 322.561 0.113
202509 -0.210 324.800 -0.213
202512 -0.220 324.054 -0.224
202603 -0.210 330.213 -0.210

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-970.42 mean?
Avenue Therapeutics (ATXI) has a E10 of $-970.42 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Avenue Therapeutics and its competitors.
Is Avenue Therapeutics' E10 too high?
Avenue Therapeutics' current E10 is $-970.42. Overall, Avenue Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' E10 compare to PTIX and EVFM?
Avenue Therapeutics' E10 of $-970.42 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Avenue Therapeutics and its competitors. Avenue Therapeutics's current E10 is $-970.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current E10 of $-970.42. The current E10 is $-970.42. Avenue Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current E10 is $-970.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avenue Therapeutics Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
31GF Score

Get the complete analysis for ATXI

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price